P184 Delay in diagnosis reduces outcome in systemic lupus erythematosus – cross sectional analysis of a german long-term study (LuLa cohort). (23rd March 2020)
- Record Type:
- Journal Article
- Title:
- P184 Delay in diagnosis reduces outcome in systemic lupus erythematosus – cross sectional analysis of a german long-term study (LuLa cohort). (23rd March 2020)
- Main Title:
- P184 Delay in diagnosis reduces outcome in systemic lupus erythematosus – cross sectional analysis of a german long-term study (LuLa cohort)
- Authors:
- Kernder, Anna
Richter, Jutta
Fischer-Betz, Rebecca
Winkler-Rohlfing, Borgi
Schneider, Matthias
Chehab, Gamal - Abstract:
- Abstract : Purpose: Our aim was to study the delay from the onset of symptoms to the diagnosis of systemic lupus erythematosus (SLE) and its association to the outcome of the disease. Methods: Information on demographics, onset of first symptoms, first physicians visit and time of diagnosis was assessed by self-reported questionnaires among SLE patients in Germany in 2010 (LuLa cohort, n=585). Disease activity (Systemic Lupus Activity Questionnaire; SLAQ), disease related damage (Brief Index of Lupus Damage; BILD) and health related quality of life were chosen as relevant proxies for outcome. Linear regression analysis was used to analyze the association to the outcome of the disease, adjusted for age, disease duration and sex. Results: Mean reported duration between the onset of symptoms and the diagnosis of SLE was 45.7 months (SD 72.6), including a mean duration of 13.2 month (SD 40.9) between the onset of symptoms and the first physicians visit. In our cohort, the mean disease duration was 17.7 years (SD 7.89). A delayed diagnosis was associated with high disease activity (SLAQ, p<0.0001, β=0.199, corr. R 2 0.068), high disease-related damage (BILD, p=0.002, β=0.137, corr. R 2 0.163) and low health-related quality of life (SF-12 physical p=0.004, β=-0.136, corr. R 2 0.125, SF-12 mental p=0.004, β=-0.143, corr. R 2 0.012) in the year 2010. The organ involvement at the time of diagnosis did not alter these results. Conclusion: The time to diagnosis was associated with aAbstract : Purpose: Our aim was to study the delay from the onset of symptoms to the diagnosis of systemic lupus erythematosus (SLE) and its association to the outcome of the disease. Methods: Information on demographics, onset of first symptoms, first physicians visit and time of diagnosis was assessed by self-reported questionnaires among SLE patients in Germany in 2010 (LuLa cohort, n=585). Disease activity (Systemic Lupus Activity Questionnaire; SLAQ), disease related damage (Brief Index of Lupus Damage; BILD) and health related quality of life were chosen as relevant proxies for outcome. Linear regression analysis was used to analyze the association to the outcome of the disease, adjusted for age, disease duration and sex. Results: Mean reported duration between the onset of symptoms and the diagnosis of SLE was 45.7 months (SD 72.6), including a mean duration of 13.2 month (SD 40.9) between the onset of symptoms and the first physicians visit. In our cohort, the mean disease duration was 17.7 years (SD 7.89). A delayed diagnosis was associated with high disease activity (SLAQ, p<0.0001, β=0.199, corr. R 2 0.068), high disease-related damage (BILD, p=0.002, β=0.137, corr. R 2 0.163) and low health-related quality of life (SF-12 physical p=0.004, β=-0.136, corr. R 2 0.125, SF-12 mental p=0.004, β=-0.143, corr. R 2 0.012) in the year 2010. The organ involvement at the time of diagnosis did not alter these results. Conclusion: The time to diagnosis was associated with a worse outcome in systemic lupus erythematosus, assessed by self-reported questionnaires for disease activity, disease-related damage and quality of life, unaffected by the organ involvement at the time of diagnosis. An early diagnosis should therefore be strived to improve the long-term outcome of the disease. German Clinical Trial Register, www.germanctr.de, DRKS00011052 Acknowledgement: The LuLa study is supported by unrestricted grants from GlaxoSmithKline and UCB Pharma. … (more)
- Is Part Of:
- Lupus science & medicine. Volume 7(2020)Supplement 1
- Journal:
- Lupus science & medicine
- Issue:
- Volume 7(2020)Supplement 1
- Issue Display:
- Volume 7, Issue 1 (2020)
- Year:
- 2020
- Volume:
- 7
- Issue:
- 1
- Issue Sort Value:
- 2020-0007-0001-0000
- Page Start:
- A120
- Page End:
- A120
- Publication Date:
- 2020-03-23
- Subjects:
- Systemic lupus erythematosus -- Periodicals
616.772005 - Journal URLs:
- http://www.bmj.com/archive ↗
http://lupus.bmj.com/ ↗ - DOI:
- 10.1136/lupus-2020-eurolupus.226 ↗
- Languages:
- English
- ISSNs:
- 2398-8851
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 19741.xml